Who we are
An independent reading of the ipamorelin literature
Bright, plain-spoken, and cited line by line — with the safety story kept in full view.
What this site is
Script Ipamorelin is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on ipamorelin. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — specifically, the safety, tolerability, and selectivity record of one growth hormone secretagogue.
We took a deliberate angle: lead with the safety and tolerability story. Plenty of pages online sell ipamorelin's upside. Fewer of them put the failed human trial, the class-level heart signal, and the thin long-term data in plain view next to the reported benefits. That's the job we set for this page — make a dense, cautious literature legible without ever drifting into hype.
About the name
The word "script" in this site's name is editorial framing, not a claim about services. "Script" is slang for a prescription — and one of the most useful things this site can tell you plainly is that ipamorelin is not a prescribable, FDA-approved medicine [3]. So the name is a bit of a deliberate counterpoint: people search for ipamorelin as though it's something you get scripted, and a big part of the honest answer is that it isn't. We occupy the position of a reader and summarizer of the literature — not a clinic, not a pharmacy, not a prescriber. Nobody here writes, fills, or fulfils a prescription, and nothing on this site is for sale.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation in the references, and where a study used a related compound rather than ipamorelin itself, we say so in the text. We keep two things rigorously separate: what controlled studies measured (cited as findings) and what the research-use community reports (clearly labeled anecdotal, not clinical evidence). We don't recommend doses, we don't promise outcomes, and we don't point you toward a place to buy anything. When the evidence runs out — which, for ipamorelin's long-term human safety, it largely does — we say that plainly rather than filling the gap with confidence the literature doesn't support.